Company Analysis Moderna
1. Summary
Advantages
- Price (71.1 $) is less than fair price (93.02 $)
- The stock's return over the last year (0.0704%) is higher than the sector average (-29.77%).
Disadvantages
- Dividends (0%) are below the sector average (0.5491%).
- Current debt level 6.75% has increased over 5 years from 1.71%.
- The company's current efficiency (ROE=-34.03%) is lower than the sector average (ROE=9.61%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
18 november 18:14 CDC approves updated COVID-19 vaccines targeting omicron variant
18 november 17:47 FDA panel recommends Pfizer and Moderna COVID-19 vaccines for children as young as 6 months old
18 november 16:57 U.S. begins rolling out COVID vaccines for young children
Other news β¨
2.3. Market efficiency
| Moderna | Healthcare | Index | |
|---|---|---|---|
| 7 days | 37.2% | -16.4% | 1.9% |
| 90 days | -17.8% | -46.1% | 6.2% |
| 1 year | 0.1% | -29.8% | 33.7% |
MRNA vs Sector: Moderna has outperformed the "Healthcare" sector by 29.84% over the past year.
MRNA vs Market: Moderna has significantly underperformed the market by -33.63% over the past year.
Stable price: MRNA is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: MRNA with weekly volatility of 0.0014% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (71.1 $) is lower than the fair price (93.02 $).
Price significantly below the fair price: The current price (71.1 $) is 30.8% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (8.96) is lower than that of the sector as a whole (48.77).
P/E vs Market: The company's P/E (8.96) is lower than that of the market as a whole (48.05).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (2.68) is lower than that of the sector as a whole (4.82).
P/BV vs Market: The company's P/BV (2.68) is lower than that of the market as a whole (3.1).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (5.5) is lower than that of the sector as a whole (33.76).
P/S vs Market: The company's P/S indicator (5.5) is lower than that of the market as a whole (10.14).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-11.06) is higher than that of the sector as a whole (-22.12).
EV/Ebitda vs Market: The company's EV/Ebitda (-11.06) is lower than that of the market as a whole (19.1).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 163.42% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (163.42%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-9.16%).
5.4. ROE
ROE vs Sector: The company's ROE (-34.03%) is lower than that of the sector as a whole (9.61%).
ROE vs Market: The company's ROE (-34.03%) is lower than that of the market as a whole (10.87%).
5.5. ROA
ROA vs Sector: The company's ROA (-25.58%) is lower than that of the sector as a whole (0.3359%).
ROA vs Market: The company's ROA (-25.58%) is lower than that of the market as a whole (6.5%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (131.22%) is higher than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (131.22%) is higher than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5491%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Selling More insider purchases by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 09.09.2024 | Klinger Shannon Thyme Chief Legal Officer |
Sale | 73.57 | 40 537 | 551 |
| 15.07.2024 | Hoge Stephen President |
Sale | 121.12 | 1 816 800 | 15 000 |
| 17.06.2024 | Hoge Stephen President |
Sale | 138.16 | 2 072 400 | 15 000 |
| 11.06.2024 | AFEYAN NOUBAR Director |
Sale | 148.34 | 30 088 100 | 202 832 |
| 10.06.2024 | Klinger Shannon Thyme Chief Legal Officer |
Sale | 148.09 | 766 810 | 5 178 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
